SCHEMBL5801394

SCHEMBL5801394

c1ccc2c(c1)Cn1c-2nc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 1.00
RAB9A P51151 8/20 1.00
HSD17B10 Q99714 6/20 1.00
NPC1 O15118 6/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
TP53 P04637 3/20 1.00
TSHR P16473 2/20 1.00
PKM P14618 2/20 1.00
HPGD P15428 6/20 0.64
MAPT P10636 7/20 0.50
MAPK1 P28482 2/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 6/20 0.48
ATM Q13315 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
LMNA P02545 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Perchlorate SCHEMBL5797378 0.91 KDM4E (0.82) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL9413470 0.85 KDM4E (0.74) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL29802287 0.83 KDM4E (0.71) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL22955317 0.81 NPC1 (0.68) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL29824916 0.81 NPC1 (0.68) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL20740186 0.78 KDM4E (1.00) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL30436694 0.77 RAB9A (0.64) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL14266173 0.77 RAB9A (0.62) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL19917859 0.75 KDM4E (0.58) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2
SCHEMBL16329999 0.73 KDM4E (0.56) KDM4ERAB9AHSD17B10NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116919953-A Application of benzimidazole amine derivative in preparation of antitumor pharmaceutical composition 广西科技大学 2023-10-24 CN claimed
CN-116919953-B Application of benzimidazole amine derivative in preparation of antitumor pharmaceutical composition 广西科技大学 2025-12-05 CN disclosed
EP-4370520-A4 TWO DIMENSIONAL BENZO[4,5]IMIDAZO[2,1-A]ISOINDOLE INCORPORATED NON-FULLERENE ELECTRON ACCEPTORS FOR ORGANIC PHOTOVOLTAIC DEVICES NAT RES COUNCIL CANADA (CA) 2025-07-23 EP disclosed
EP-4370520-A1 TWO DIMENSIONAL BENZO[4,5]IMIDAZO[2,1-A]ISOINDOLE INCORPORATED NON-FULLERENE ELECTRON ACCEPTORS FOR ORGANIC PHOTOVOLTAIC DEVICES National Research Council of Canada (CA) 2024-05-22 EP disclosed
EP-4370520-A1 TWO DIMENSIONAL BENZO[4,5]IMIDAZO[2,1-A]ISOINDOLE INCORPORATED NON-FULLERENE ELECTRON ACCEPTORS FOR ORGANIC PHOTOVOLTAIC DEVICES National Research Council of Canada (CA) 2024-05-22 EP disclosed
CN-116919953-A Application of benzimidazole amine derivative in preparation of antitumor pharmaceutical composition 广西科技大学 2023-10-24 CN disclosed
CN-116919953-A Application of benzimidazole amine derivative in preparation of antitumor pharmaceutical composition 广西科技大学 2023-10-24 CN disclosed
WO-2023283728-A1 TWO DIMENSIONAL BENZO[4,5]IMIDAZO[2,1-A]ISOINDOLE INCORPORATED NON-FULLERENE ELECTRON ACCEPTORS FOR ORGANIC PHOTOVOLTAIC DEVICES NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2023-01-19 WO disclosed
WO-2023283728-A1 TWO DIMENSIONAL BENZO[4,5]IMIDAZO[2,1-A]ISOINDOLE INCORPORATED NON-FULLERENE ELECTRON ACCEPTORS FOR ORGANIC PHOTOVOLTAIC DEVICES NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2023-01-19 WO disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
WO-2010011964-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-01-28 WO disclosed
WO-2006030127-A1 COMPOSITION COMPRISING AT LEAST ONE SUBSTITUTED CARBOCYANINE DERIVATIVE, KERATIN FIBRE TREATMENT METHOD USING SAME, ASSOCIATED DEVICE AND USE THEREOF L'OREAL (FR) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB KDM4E 2997/4885RAB9A 3454/4885HSD17B10 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.